Jpmorgan Chase & Co »

Kyverna Therapeutics shares owned by Jpmorgan Chase & Co

Quarter-by-quarter ownership of Kyverna Therapeutics shares owned by Jpmorgan Chase & Co from 13F filings

Historical chart of Jpmorgan Chase & Co investment in Kyverna Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Kyverna Therapeutics held by Jpmorgan Chase & Co consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Kyverna Therapeutics by Jpmorgan Chase & Co

Quarter filed Position value Share count Share price at filing
2024-03-31 $21M 845k 24.84

More positions owned by Jpmorgan Chase & Co

Microsoft Corp Common (MSFT)
Nvidia Corporation Common (NVDA)
SPDR S&P 500 ETF Ser 1 S&P Common (SPY)
Amazon Common (AMZN)
Apple Common (AAPL)
Meta Platforms Common (META)
Eli Lilly & Co Common (LLY)
Alphabet Common (GOOG)
Mastercard Incorporated Common (MA)
Unitedhealth Group Common (UNH)
Ishares Core S&p 500 Etf Fund (IVV)
Vanguard index Fds S&P 500 ETF Common (VOO)
Abbvie Common (ABBV)
Exxon Mobil Corp Common (XOM)
Alphabet Common (GOOGL)

View all positions for Jpmorgan Chase & Co

Top funds holding Kyverna Therapeutics

Vida Ventures Advisors
Northpond Ventures
Bain Capital Life Sciences Investors
Deerfield Management Company
Jennison Associates
T. Rowe Price Associates
Insight Holdings
Commodore Capital
Jpmorgan Chase & Co
BlackRock
Millennium Management
Henderson Group
Adage Capital Partners GP
Citadel Advisors
Logos Global Management

View all funds holding Kyverna Therapeutics